Allogene Therapeutics, Inc. Research and Development Expense
Allogene Therapeutics, Inc. (ALLO) reported Research and Development Expense of $30.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- Allogene Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $30.72M, a 23.50% decline year-over-year.
- Allogene Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $32.00M, a 36.25% decline year-over-year.
- Allogene Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $28.63M, a 36.33% decline year-over-year.
- Allogene Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $31.16M, a 30.30% decline year-over-year.
- Allogene Therapeutics, Inc. research and development expense for fiscal 2025 was $150.15M, a 21.92% decline from fiscal 2024.
- Allogene Therapeutics, Inc. research and development expense for fiscal 2024 was $192.30M, a 20.84% decline from fiscal 2023.
- Allogene Therapeutics, Inc. research and development expense for fiscal 2023 was $242.91M, a 5.25% decline from fiscal 2022.
- Allogene Therapeutics, Inc. research and development expense for fiscal 2022 was $256.39M, a 16.45% increase from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $30.72M 10-Q · filed 2026-08-12 | $62.72M 10-Q · filed 2026-08-12 | $91.36M derived: sum of 3 quarters · filed 2026-08-12 | $122.52M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $32.00M 10-Q · filed 2026-05-13 | $60.63M derived: sum of 2 quarters · filed 2026-05-13 | $91.80M derived: sum of 3 quarters · filed 2026-05-13 | $131.96M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $28.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $59.80M derived: sum of 2 quarters · filed 2026-03-12 | $99.95M derived: sum of 3 quarters · filed 2026-08-12 | $150.15M 10-K · filed 2026-03-12 | |
| 2025-09-30 | $31.16M 10-Q · filed 2025-11-06 | $71.32M derived: sum of 2 quarters · filed 2026-08-12 | $121.52M 10-Q · filed 2025-11-06 | $166.49M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | $40.16M 10-Q · filed 2026-08-12 | $90.36M 10-Q · filed 2026-08-12 | $135.33M derived: sum of 3 quarters · filed 2026-08-12 | $180.04M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | $50.20M 10-Q · filed 2026-05-13 | $95.17M derived: sum of 2 quarters · filed 2026-05-13 | $139.88M derived: sum of 3 quarters · filed 2026-05-13 | $190.24M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | $44.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $89.69M derived: sum of 2 quarters · filed 2026-03-12 | $140.04M derived: sum of 3 quarters · filed 2026-03-12 | $192.30M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $44.71M 10-Q · filed 2025-11-06 | $95.07M derived: sum of 2 quarters · filed 2025-11-06 | $147.33M 10-Q · filed 2025-11-06 | $201.99M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $50.35M 10-Q · filed 2025-08-13 | $102.61M 10-Q · filed 2025-08-13 | $157.28M derived: sum of 3 quarters · filed 2025-08-13 | $203.25M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $52.26M 10-Q · filed 2025-05-13 | $106.92M derived: sum of 2 quarters · filed 2025-05-13 | $152.90M derived: sum of 3 quarters · filed 2025-05-13 | $214.94M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $54.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $100.64M derived: sum of 2 quarters · filed 2025-03-13 | $162.68M derived: sum of 3 quarters · filed 2025-03-13 | $242.91M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $45.98M 10-Q · filed 2024-11-07 | $108.02M derived: sum of 2 quarters · filed 2024-11-07 | $188.25M 10-Q · filed 2024-11-07 | $263.67M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $62.04M 10-Q · filed 2024-08-07 | $142.28M 10-Q · filed 2024-08-07 | $217.69M derived: sum of 3 quarters · filed 2024-08-07 | $281.34M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $80.24M 10-Q · filed 2024-05-13 | $155.66M derived: sum of 2 quarters · filed 2024-05-13 | $219.30M derived: sum of 3 quarters · filed 2024-05-13 | $276.47M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $75.42M derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | $139.06M derived: sum of 2 quarters · filed 2024-03-14 | $196.23M derived: sum of 3 quarters · filed 2024-03-14 | $256.39M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $63.64M 10-K · filed 2024-03-14 | $120.81M derived: sum of 2 quarters · filed 2024-03-14 | $180.97M 10-K · filed 2024-03-14 | $234.95M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $57.17M 10-K · filed 2024-03-14 | $117.33M 10-K · filed 2024-03-14 | $171.31M derived: sum of 3 quarters · filed 2024-03-14 | $230.03M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $60.16M 10-K · filed 2024-03-14 | $114.14M derived: sum of 2 quarters · filed 2024-03-14 | $172.86M derived: sum of 3 quarters · filed 2024-03-14 | $225.15M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $53.98M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $112.70M derived: sum of 2 quarters · filed 2024-03-14 | $164.99M derived: sum of 3 quarters · filed 2024-03-14 | $220.18M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $58.72M 10-Q · filed 2022-11-02 | $111.01M derived: sum of 2 quarters · filed 2022-11-02 | $166.19M 10-Q · filed 2022-11-02 | $218.42M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $52.29M 10-Q · filed 2022-08-09 | $107.47M 10-Q · filed 2022-08-09 | $159.70M derived: sum of 3 quarters · filed 2024-03-14 | $211.12M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $55.18M 10-Q · filed 2022-05-04 | $107.41M derived: sum of 2 quarters · filed 2024-03-14 | $158.83M derived: sum of 3 quarters · filed 2024-03-14 | $206.13M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $52.23M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $103.65M derived: sum of 2 quarters · filed 2024-03-14 | $150.94M derived: sum of 3 quarters · filed 2024-03-14 | $192.99M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $51.42M 10-Q · filed 2021-11-04 | $98.72M derived: sum of 2 quarters · filed 2021-11-04 | $140.76M 10-Q · filed 2021-11-04 | $190.12M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $47.30M 10-Q · filed 2021-08-04 | $89.34M 10-Q · filed 2021-08-04 | $138.70M derived: sum of 3 quarters · filed 2022-02-23 | $178.70M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $42.04M 10-Q · filed 2021-05-05 | $91.41M derived: sum of 2 quarters · filed 2022-02-23 | $131.40M derived: sum of 3 quarters · filed 2022-02-23 | $163.17M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $49.36M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $89.36M derived: sum of 2 quarters · filed 2022-02-23 | $121.13M derived: sum of 3 quarters · filed 2022-02-23 | $144.53M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $39.99M 10-Q · filed 2020-11-04 | $71.77M derived: sum of 2 quarters · filed 2020-11-04 | $95.17M 10-Q · filed 2020-11-04 | $113.68M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-06-30 | $31.77M 10-Q · filed 2020-08-05 | $55.18M 10-Q · filed 2020-08-05 | $73.68M derived: sum of 3 quarters · filed 2021-02-25 | $84.55M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2019-03-31 | $23.40M 10-Q · filed 2020-05-06 | $41.91M derived: sum of 2 quarters · filed 2021-02-25 | $52.78M derived: sum of 3 quarters · filed 2021-02-25 | $175.26M derived: sum of 4 quarters · filed 2021-02-25 | |
| 2018-12-31 | $18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $29.37M derived: sum of 2 quarters · filed 2021-02-25 | $151.86M derived: sum of 3 quarters · filed 2021-02-25 | $151.86M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $10.87M 10-Q · filed 2019-11-05 | $133.36M derived: sum of 2 quarters · filed 2019-11-05 | $133.36M 10-Q · filed 2019-11-05 | ||
| 2018-06-30 | $122.49M 10-Q · filed 2019-08-07 | $122.49M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |